Meeting
2019 Genitourinary Cancers Symposium
A phase II study of nivolumab in patients with high-risk biochemically recurrent (BCR) prostate cancer (PCa).
Authors
David Johnson Einstein
Beth-Israel Deaconess Medcl Ctr, Boston, MA
David Johnson Einstein , Xiao X. Wei , Lillian Werner , Huihui Ye , Carla Calagua , Glenn Bubley , Steven P. Balk
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer,Prostate Cancer
Sub Track
Prostate Cancer - Advanced Disease
Clinical Trial Registration Number
NCT03637543
Citation
J Clin Oncol 37, 2019 (suppl 7S; abstr TPS341)
DOI
10.1200/JCO.2019.37.7_suppl.TPS341
Abstract #
TPS341
Poster Bd #
N17
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
A phase II single-arm study of nivolumab and ipilimumab (Nivo/Ipi) in previously treated classical Kaposi sarcoma (CKS).
First Author: Alona Zer
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Prognostic value of PD-L1+CD4+ T cells in non-small cell lung cancer (NSCLC) patients treated with a PD-1 inhibitor.
First Author: Kiriaki E. Vetsika
Poster
2016 ASCO Annual Meeting
Assessment of PD-L1 expression and tumor associated immune cells in pediatric cancer tissues.
First Author: Robbie G. Majzner
First Author: Sarah Derks